{
    "clinical_study": {
        "@rank": "117762", 
        "arm_group": [
            {
                "arm_group_label": "Treatment with ADSCs transplantation", 
                "arm_group_type": "Experimental", 
                "description": "4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous"
            }, 
            {
                "arm_group_label": "Treatment without ADSCs transplantation", 
                "arm_group_type": "No Intervention", 
                "description": "Only intervention: laminectomy"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess the safety and effect of autologous adipose derived stem\n      cell (ADSCs) transplantation in acute spinal cord injury patients.\n\n        1. To assess the safety of autologous ADSCs transplantation in acute spinal cord injury\n           and the complication after ADSCs transplantation.\n\n        2. To evaluate the effect of ADSCs isolation and expansion procedure.\n\n        3. To determine if functional outcome is improved following ADSCs transplantation in acute\n           spinal cord injury patient, using pre-transplantation spinal cord function as the\n           control."
        }, 
        "brief_title": "Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Spinal Cord Injury", 
        "condition_browse": {
            "mesh_term": [
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "The research has carried out in Phase II which is designed as randomized controlled trials.\n\n      Selection of patients began in Feb,2013, 48 patients are divided in two group according to a\n      2:1 ratio (the number of candidates as treated: the candidates as control).\n\n      The effectiveness of preliminary trial are evaluated by assessing Frankel/ASIA motor grade,\n      measuring electrophysiological parameters, enhanced MRI and urinary and bowel function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be able to give voluntary (patients may not be able to write) consent.\n\n          -  Must be able to understand study information provided to him.\n\n          -  Patients with complete spinal cord < 2 weeks in acute category\n\n          -  The level of spinal cord injury must be categorized at A level in terms of ASIA\n             Impairment scale.\n\n          -  Age should be between 19-60 years\n\n          -  Both male and female\n\n        Exclusion Criteria:\n\n          -  Support respiration by machine\n\n          -  Melanoma within 5 years\n\n          -  Infectious diseases including HIV and Hepatitis B, C\n\n          -  Brain damage or multiple trauma\n\n          -  Body temperature higher 38 \u2103 or acute disorder\n\n          -  Anemia or thrombocytopenia\n\n          -  Angina , myocardial infarction , heart disease , embolic disease , chronic renal\n             failure, glomerular disease and chronic obstructive pulmonary disease.\n\n          -  Congenital or acquired immunodeficiency disorder\n\n          -  Muscular dystrophy or muscle stiffness\n\n          -  Non-conscious or voice disorders\n\n          -  Treatment with cytotoxic drugs ( immunosuppressive drugs , corticosteroids and\n             cytotoxic drugs) during the clinical trials .\n\n          -  Participating in another clinical trial within 3 months\n\n          -  Other serious disease or disorder can seriously affect the ability to participate in\n             research.\n\n          -  Women who are pregnant or lactating .\n\n          -  Allergy to antibiotics and anesthetics .\n\n          -  Do not agree to participate in research"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034669", 
            "org_study_id": "TP-VD-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment with ADSCs transplantation", 
                "description": "surgical laminectomy with glial scar resection", 
                "intervention_name": "Laminectomy", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Treatment with ADSCs transplantation", 
                "description": "ADSCs injection into Intradural space at damage site", 
                "intervention_name": "Intradural space", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Treatment with ADSCs transplantation", 
                "description": "ADSCs Intrathecal into lumbar puncture", 
                "intervention_name": "Intrathecal", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Treatment with ADSCs transplantation", 
                "description": "ADSCs intravenous", 
                "intervention_name": "Intravenous", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Acute Spinal cord Injury, Adipose derived stem cells", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "triphuocbio@gmail.com", 
                "last_name": "Phuc Ba Duong, MD", 
                "phone": "+17143607716"
            }, 
            "contact_backup": {
                "email": "dinhhoaykhoa@yahoo.com", 
                "last_name": "Hoa D Nguyen, MSc, MD", 
                "phone": "+84904613833"
            }, 
            "facility": {
                "address": {
                    "city": "Hanoi", 
                    "country": "Vietnam"
                }, 
                "name": "Vietnamese- German Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Vietnam"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Study of Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Completely Acute Spinal Cord Injury.", 
        "overall_contact": {
            "email": "triphuocbio@gmail.com", 
            "last_name": "Phuc Ba Duong, MD", 
            "phone": "+17143607716"
        }, 
        "overall_contact_backup": {
            "email": "dinhhoaykhoa@yahoo.com", 
            "last_name": "Hoa D Nguyen, MD", 
            "phone": "+84904613833"
        }, 
        "overall_official": [
            {
                "affiliation": "Tri Phuoc Biotechnology., JSC", 
                "last_name": "Phuc Ba Duong, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Vietnamese- German Hospital", 
                "last_name": "Hoa D Nguyen, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Vietnam: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of Participants with adverse events is as a measure of safety and tolerability after ADSC transplantation. Adverse events can be impaired liver and kidney, immunosuppression or immune deficiency, hypersensitivity, anaphylactic shock, meningitis symptoms, etc.", 
            "measure": "Number of Participants with adverse events after transplantation.", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034669"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients take MRI at the lesion site before each injection and after transplantation 6 months, 12 months, 24 months. MRI at the lesion site shows spinal cord edema level is reduced or not.", 
                "measure": "Changes of spinal cord edema in the MRI at the lesion site", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Bladder pressure monitory to assess ability to feel and control urination and bowel.", 
                "measure": "Urinary and bowel function Improvement", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Comparison the electromyography (EMG) score during contraction of given muscles before each injection and after transplantation 6 months, 12 months and 24 months.", 
                "measure": "Muscle contraction force measurement", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Patients are assess improvement level based on American Spinal Injury Assessment scale of A,B,C,D or E before and after transplantation.", 
                "measure": "Significant clinical improvement in ASIA impairment scale and general condition.", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Tri Phuoc Biotechnology., JSC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tri Phuoc Biotechnology., JSC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}